Entrada Therapeutics (TRDA) Stock Price, News & Analysis

Company Overview

Entrada Therapeutics, Inc., a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1. The company also offers ENTR-601-45 and ENTR-601-50, which are in preclinical trail for the treatment of Duchenne muscular dystrophy; and ENTR-501, an intracellular thymidine phosphorylase enzyme replacement therapy, which is in preclinical trail for the treatment of mitochondrial neurogastrointestinal encephalomyopathy. Entrada Therapeutics, Inc. has a strategic collaboration and license agreement with Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize ENTR-701. The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.

Key Stats

• Today's Range: $17.90 to $18.95
• 50-Day Range: $13.65 to $19.96
• 52-Week Range: $10.95 to $20.49
• Volume: 95,865 shs
• Average Volume: 135,103 shs
• Market Capitalization: $703.50 million
• P/E Ratio: 11.82
• Dividend Yield: N/A
• Price Target: $24.00
• Consensus Rating: Buy

Entrada Therapeutics Stock Analysis - MarketRank™

Entrada Therapeutics scored higher than 51% of companies evaluated by MarketBeat, and ranked 574th out of 953 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Entrada Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Entrada Therapeutics has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Entrada Therapeutics are expected to decrease in the coming year, from $1.07 to ($3.38) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Entrada Therapeutics is 11.82, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 117.37.

Price to Earnings Ratio vs. Sector

The P/E ratio of Entrada Therapeutics is 11.82, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 77.93.

Price to Book Value per Share Ratio

Entrada Therapeutics has a P/B Ratio of 1.67. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

7.68% of the float of Entrada Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Entrada Therapeutics has a short interest ratio ("days to cover") of 11.7, which indicates bearish sentiment.

Change versus previous month

Short interest in Entrada Therapeutics has recently increased by 0.61%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Entrada Therapeutics does not currently pay a dividend.

Dividend Growth

Entrada Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

7.68% of the float of Entrada Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Entrada Therapeutics has a short interest ratio ("days to cover") of 11.7, which indicates bearish sentiment.

Change versus previous month

Short interest in Entrada Therapeutics has recently increased by 0.61%, indicating that investor sentiment is decreasing.

News and Social Media

• Score: 2.6 / 5
• News Sentiment: N/A

News Sentiment

Entrada Therapeutics has a news sentiment score of 1.76. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.49 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Entrada Therapeutics this week, compared to 2 articles on an average week.

Search Interest

Only 1 people have searched for TRDA on MarketBeat in the last 30 days. This is a decrease of -80% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Entrada Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $410,816.00 in company stock.

Percentage Held by Insiders

Only 7.59% of the stock of Entrada Therapeutics is held by insiders.

Percentage Held by Institutions

86.39% of the stock of Entrada Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

TRDA Stock Analysis - Frequently Asked Questions

How have TRDA shares performed this year?

Entrada Therapeutics' stock was trading at $15.09 on January 1st, 2024. Since then, TRDA shares have increased by 24.6% and is now trading at $18.80.
View the best growth stocks for 2024 here.

How were Entrada Therapeutics' earnings last quarter?

Entrada Therapeutics, Inc. (NASDAQ:TRDA) announced its quarterly earnings results on Tuesday, August, 13th. The company reported $1.55 EPS for the quarter, beating analysts' consensus estimates of $0.65 by $0.90. The firm had revenue of $94.69 million for the quarter, compared to analyst estimates of $55 million. Entrada Therapeutics had a trailing twelve-month return on equity of 16.11% and a net margin of 25.53%.

When did Entrada Therapeutics IPO?

Entrada Therapeutics (TRDA) raised $182 million in an IPO on Friday, October 29th 2021. The company issued 9,075,000 shares at a price of $19.00-$21.00 per share.

Who are Entrada Therapeutics' major shareholders?

Entrada Therapeutics' top institutional investors include FMR LLC (4.66%), Janus Henderson Group PLC (4.57%), Wellington Management Group LLP (2.75%) and Geode Capital Management LLC (1.54%). Insiders that own company stock include Bros Advisors Lp Baker, Dipal Doshi, Natarajan Sethuraman, Nathan J Dowden, Kory James Wentworth, Peter S Kim, Nerissa Kreher and John F Crowley.
View institutional ownership trends.

How do I buy shares of Entrada Therapeutics?

Shares of TRDA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Entrada Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Entrada Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), Netflix (NFLX), Palo Alto Networks (PANW) and Invesco QQQ (QQQ).

Company Calendar

• Last Earnings: 8/13/2024
• Today: 11/23/2024
• Fiscal Year End: 12/31/2024
• Next Earnings (Estimated): 3/12/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:TRDA
• CUSIP: N/A
• CIK: 1689375
• Web: www.entradatx.com
• Phone: 857-520-9158
• Fax: N/A
• Employees: 110
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $24.00
• High Stock Price Target: $28.00
• Low Stock Price Target: $20.00
• Potential Upside/Downside: +27.7%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Most Recent Fiscal Year): $1.59
• Trailing P/E Ratio: 11.82
• Forward P/E Ratio: 17.57
• P/E Growth: N/A
• Net Income: $-6,680,000.00
• Net Margins: 25.53%
• Pretax Margin: 35.51%
• Return on Equity: 16.11%
• Return on Assets: 10.39%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 6.59
• Quick Ratio: 6.59

Sales & Book Value

• Annual Sales: $129.01 million
• Price / Sales: 5.45
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $11.29 per share
• Price / Book: 1.67

Miscellaneous

• Outstanding Shares: 37,420,000
• Free Float: 34,580,000
• Market Cap: $703.50 million
• Optionable: Optionable
• Beta: -0.26